Editorial: Microorganisms and their derivatives for cancer therapy
- PMID: 36714005
- PMCID: PMC9880520
- DOI: 10.3389/fbioe.2023.1137341
Editorial: Microorganisms and their derivatives for cancer therapy
Keywords: bacterial products; bacteriolytic therapy; bacteriotherapy; cancer therapy; drug delivery; microorganism.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Comment on
- Editorial on the Research Topic Microorganisms and their derivatives for cancer therapy
References
-
- Kurtz C. B., Millet Y. A., Puurunen M. K., Perreault M., Charbonneau M. R., Isabella V. M., et al. (2019). An engineered E. coli Nissle improves hyperammonemia and survival in mice and shows dose-dependent exposure in healthy humans. Sci. Transl. Med. 11 (475), eaau7975. 10.1126/scitranslmed.aau7975 - DOI - PubMed
-
- Liu M., O'Connor R. S., Trefely S., Graham K., Snyder N. W., Beatty G. L. (2019). Metabolic rewiring of macrophages by CpG potentiates clearance of cancer cells and overcomes tumor-expressed CD47-mediated 'don't-eat-me' signal. Nat. Immunol. 20 (3), 265–275. 10.1038/s41590-018-0292-y - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources
